May 29
Denteric Commences a Phase I Safety Study in Patients with Early Alzheimer’s Disease
Read moreVale Rob Knowles
The Honourable Rob Knowles AO, a prominent former Victorian Health Minister, passed away on 29 April 2026 at the age of 78. He was a director on the board of Brandon BioCatalyst from December 2019 until April 2025. Rob made significant contributions to the health and life sciences sector and to the broader Australian health system over many years.
Brandon Capital extends its heartfelt condolences to Mr Knowles’ wife Carmel, and to his children, grandchildren, extended family and friends.
Brandon BioCatalyst is the largest life science investment fund in Australia and New Zealand. We are a unique collaboration between major Australian superannuation funds, CSL, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals.
Learn more about who we areA clinical stage company developing treatment for hot flashes in cancer survivors undergoing endocrine therapy
View ProjectDeveloping disease-modifying mitochondrial therapeutics for neurodegenerative disorders
View ProjectDeveloping the next generation of CAR-T cell therapies to treat solid cancers
View ProjectCombining non-opioid analgesics and biopolymers to deliver weeks of localised pain management
View ProjectUnlocking the potential of N-myristoyltransferase (NMT) to develop precision medicines for a range of diseases including cancer and viral infections
View ProjectGlyscend is developing novel non-absorbable polymers that are orally-delivered for the treatment of Type 2 Diabetes.
View ProjectOur vision is to perform world-class medical research that focuses on the molecular basis of health and disease. The specific areas of our research include cancer, molecular bioscience, metabolic and musculoskeletal medicine, infection and immunity.
ViewThe Malaghan Institute of Medical Research is New Zealand’s leading independent biomedical research institute, with a history spanning over five decades. The Institute’s research centers on the immune system, and how it may be harnessed to treat human disease. Pioneering research programmes explore fields of immunotherapy such as cancer, asthma and allergy, infectious diseases, gut health and brain health.
ViewThe Curtin Health Innovation Research Institute (CHIRI) is dedicated to developing new treatments for diseases that more commonly occur with older age.
ViewBrandon BioCatalyst is innovation in action: We provide a path for taking medical science from conception into the real world.
Our Venture capital model is unique. We don’t simply provide investment, we partner with entrepreneurs to create businesses, run companies and everything necessary to ensure our investments succeed.
Learn moreDenteric Commences a Phase I Safety Study in Patients with Early Alzheimer’s Disease
Read moreOncoRes Medical today announced it has closed an AUD $27M private funding round (‘the Funding round’) to progress clinical development and regulatory milestones for its Quantitative Micro-Elastography (QME) Imaging System, Elora™.
Read morePolyActiva Chief Strategy Officer Vanessa Waddell on Raising, Rejection, and the Road Ahead
Read more